A quick overview of other recent news relating to diabetes management and/or CGMs. Just in case you missed these!
TAD 2026 - Talking About Diabetes UK Event
Save the date! TAD is back and this year will be held in London on 11th July. Tickets are by allotted from a ballot with info released via social media. Follow on X #TAD2026.
The day long event is especially for those with diabetes where you can hear from others with the condition. Previous speakers have included James Norton, Ed Gamble and top NHS Specialist for Type 1, Professor Partha Kar.
NHS update for T1 rollout of Hybrid-Closed Loop
A recent post on X by Prof. Partha Kar highlighted that hybrid closed loop is now enabling over 50,000 type 1s, children and women going through pregnancy, to manage their glucose levels. Prof Kar also confirmed that funding of £347 million is secured going forward to 2029 to enable hybrid-closed loops to be rolled out to adults with T1D, which should accelerate over the next 3 years.
Phones in schools (UK)
Following the UK's Education Secretary's comments that schools should not allow pupils to use phones in school a number of parents and carers of children managing type 1 diabetes have expressed their concern at the approach.
Partha Kar, NHS Diabetes Specialist posted the following on X:
There was also a response from Breakthrough T1D:
A reminder that current government guidelines, last updated 19th January 2026, state:
Source: https://www.gov.uk/government/publications/mobile-phones-in-schools/mobile-phones-in-schools
Teplizumab approved in Europe to delay onset of type 1 diabetes
Teplizumab, marketed in Europe as Teizeild, has received approval from the European Commission for use in people with stage 2 type 1 diabetes, marking a significant step towards delaying progression to clinical diagnosis.
Teplizumab is the first disease-modifying therapy shown to delay the onset of type 1 diabetes in people at high risk. The decision marks a shift towards earlier intervention in type 1 diabetes, building on regulatory progress already made in the UK.
Teplizumab is an immunotherapy designed to slow the autoimmune process that leads to type 1 diabetes. Clinical trials have shown that a single treatment course can delay progression to clinical diagnosis by around two to three years in people with early-stage disease.
What does this mean for the UK?
In the UK, teplizumab has already been approved by the Medicines and Healthcare products Regulatory Agency (MHRA). However, it is not yet available through the NHS. Access now depends on a decision from the National Institute for Health and Care Excellence (NICE), which assesses whether new treatments should be routinely funded based on clinical benefit and cost effectiveness.
Until NICE completes its appraisal, teplizumab cannot be prescribed within standard NHS care, despite regulatory approval.
For families identified through screening programmes or research studies as being at high risk of developing type 1 diabetes, teplizumab represents a new and fundamentally different approach — one that focuses on delaying disease onset rather than managing symptoms after diagnosis.
Did you miss Alive and Pumped?
Alive and Pumped, from Revolve Comics, is the sixth comic in a series that uses storytelling to explain key aspects of type 1 diabetes and is free to download.
This latest edition looks ahead. It explores prediction of type 1 diabetes, antibodies, and the potential role of immunotherapy, alongside the rapid growth in wearable diabetes technology. The story follows Aiko, a young hero who encounters both early risk prediction and modern tech, showing how insulin and technology work together in practice.
Alive and Pumped sits alongside other titles in the Revolve Comics series. Earlier comics cover topics including diagnosis, insulin, daily management, hospital care, and living with type 1 diabetes. They are aimed at younger readers and families, but are also used more widely by healthcare teams as educational tools.
The series was developed to make diabetes education more accessible, using comics to bridge clinical information and lived experience. It has been created with clinical input and direction from diabetes consultants Prof Partha Kar and Mayank Patel.
https://revolvecomics.com/read-diabetes-type-1-comics/
__________
Disclaimer
Blogs and publications on this website are independent of any involvement by medtech companies or diabetes related charities. To ensure there is no bias, we do not accept any products, freebies or other material from any medtech provider. Except where credited otherwise, all materials are copyright ©️What CGM.
What CGM is not associated or affiliated with Abbott or FreeStyle Libre. Content here and on our websitewww.whatcgm.com does not constitute medical advice or replace the relationship between you and healthcare professionals nor the advice you receive from them.
The author of this blog has type 1 diabetes and uses a CGM on NHS prescription.
Leave a comment (all fields required). Please note, we are unable to respond to individual comments posted here.